Regeneron Pharmaceuticals Inc. (REGN) announced that the U.S. Food and Drug Administration has accepted for review the Company's supplemental Biologics License Application or sBLA for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Under the Prescription Drug User Fee Act or PDUFA, the goal for a standard review of an sBLA is ten months from submission, for a target action date of July 30, 2012.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.